Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA

JCO Precision Oncology

Volumn 2, Issue , 2018, Pages 1-14

  Dagogo Jack, Ibiayi ^a   Brannon, A Rose ^b   Ferris, Lorin A ^a   Campbell, Catarina D ^b   Lin, Jessica J ^a   Schultz, Katherine R ^a   Ackil, Jennifer ^a   Stevens, Sara ^a   Dardaei, Leila ^a   Yoda, Satoshi ^a   Hubbeling, Harper ^a   Digumarthy, Subba R ^a   Riester, Markus ^b   Hata, Aaron N ^a   Sequist, Lecia V ^a   Lennes, Inga T ^a   Iafrate, Anthony John ^a   Heist, Rebecca S ^a   Azzoli, Christopher G ^a   Farago, Anna F ^a   Engelman, Jeffrey A ^b   Lennerz, Jochen K ^a   Benes, Cyril H ^a   Leary, Rebecca J ^b   Shaw, Alice T ^a   Gainor, Justin F ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85077489123     PISSN: None     EISSN: 24734284     Source Type: Journal    
DOI: 10.1200/PO.17.00160     Document Type: Article

References (25)

1. Lin JJ, Riely GJ, Shaw AT: Targeting ALK: Precision medicine takes on drug resistance. Cancer Discov 7:137-155, 2017
2. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253, 2009
3. Solomon BJ, Mok T, Kim DW, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167-2177, 2014
4. Kim DW, Mehra R, Tan DS, et al: Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): Updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 17:452-463, 2016
5. Shaw AT, Gandhi L, Gadgeel S, et al: Alectinib in ALK-positive, crizotinib-resistant, non-smallcell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol 17:234-242, 2016
6. Kim DW, Tiseo M, Ahn MJ, et al: Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: A randomized, multicenter phase II trial. J Clin Oncol 35:2490-2498, 2017
7. Gainor JF, Dardaei L, Yoda S, et al: Molecular mechanisms of resistance to first-and secondgeneration ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6:1118-1133, 2016
8. Oxnard GR, Thress KS, Alden RS, et al: Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34:3375-3382, 2016
9. Sacher AG, Paweletz C, Dahlberg SE, et al: Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2:1014-1022, 2016
10. Oxnard GR, Paweletz CP, Sholl LM: Genomic analysis of plasma cell-free DNA in patients with cancer. JAMA Oncol 3:740-741, 2017
11. Paweletz CP, Sacher AG, Raymond CK, et al: Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res 22:915-922, 2016
12. Schwaederlé MC, Patel SP, Husain H, et al: Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res 23:5101-5111, 2017
13. Thompson JC, Yee SS, Troxel AB, et al: Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res 22:5772-5782, 2016
14. Zheng Z, Liebers M, Zhelyazkova B, et al: Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 20:1479-1484, 2014
15. Sholl LM, Do K, Shivdasani P, et al: Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight 1:e87062, 2016
16. Frampton GM, Fichtenholtz A, Otto GA, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023-1031, 2013
17. Conde E, Hernandez S, Prieto M, et al: Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. Expert Rev Mol Diagn 16:707-713, 2016
18. Curigliano G, Gómez Pardo P, Meric-Bernstam F, et al: Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. Breast 28:191-198, 2016
19. Cibulskis K, Lawrence MS, Carter SL, et al: Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31:213-219, 2013
20. Ye K, Schulz MH, Long Q, et al: Pindel: A pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25:2865-2871, 2009
21. Schröder J, Hsu A, Boyle SE, et al: Socrates: Identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. Bioinformatics 30:1064-1072, 2014
22. Riester M, Singh AP, Brannon AR, et al: PureCN: Copy number calling and SNV classification using targeted short read sequencing. Source Code Biol Med 11:13, 2016
23. Katayama R, Friboulet L, Koike S, et al: Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20:5686-5696, 2014
24. Solomon B, Bauer TM, Felip E, et al: Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). J Clin Oncol 34, 2016 (suppl 15; abstr 9009)
25. Chabon JJ, Simmons AD, Lovejoy AF, et al: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815, 2016